These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 27209087)
21. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma. Lumsden AJ; Codde JP; Van der Meide PH; Gray BN Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226 [TBL] [Abstract][Full Text] [Related]
22. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. Huang Y; Ma C; Zhang Q; Ye J; Wang F; Zhang Y; Hunborg P; Varvares MA; Hoft DF; Hsueh EC; Peng G Oncotarget; 2015 Jul; 6(19):17462-78. PubMed ID: 25968569 [TBL] [Abstract][Full Text] [Related]
23. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. Gnerlich JL; Mitchem JB; Weir JS; Sankpal NV; Kashiwagi H; Belt BA; Porembka MR; Herndon JM; Eberlein TJ; Goedegebuure P; Linehan DC J Immunol; 2010 Oct; 185(7):4063-71. PubMed ID: 20805420 [TBL] [Abstract][Full Text] [Related]
24. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma. Mendiratta SK; Quezada A; Matar M; Thull NM; Bishop JS; Nordstrom JL; Pericle F Hum Gene Ther; 2000 Sep; 11(13):1851-62. PubMed ID: 10986558 [TBL] [Abstract][Full Text] [Related]
25. T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice. Liu W; Guo W; Shen L; Chen Z; Luo Q; Luo X; Feng G; Shu Y; Gu Y; Xu Q; Sun Y Oncotarget; 2017 Jan; 8(5):7586-7597. PubMed ID: 27935860 [TBL] [Abstract][Full Text] [Related]
26. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes. Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344 [TBL] [Abstract][Full Text] [Related]
27. α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response. Hahn T; Jagadish B; Mash EA; Garrison K; Akporiaye ET Breast Cancer Res; 2011 Jan; 13(1):R4. PubMed ID: 21232138 [TBL] [Abstract][Full Text] [Related]
28. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy. Ohno Y; Toyoshima Y; Yurino H; Monma N; Xiang H; Sumida K; Kaneumi S; Terada S; Hashimoto S; Ikeo K; Homma S; Kawamura H; Takahashi N; Taketomi A; Kitamura H Cancer Sci; 2017 Oct; 108(10):1959-1966. PubMed ID: 28746799 [TBL] [Abstract][Full Text] [Related]
29. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446 [TBL] [Abstract][Full Text] [Related]
30. Potent antitumor activity of interleukin-27. Hisada M; Kamiya S; Fujita K; Belladonna ML; Aoki T; Koyanagi Y; Mizuguchi J; Yoshimoto T Cancer Res; 2004 Feb; 64(3):1152-6. PubMed ID: 14871851 [TBL] [Abstract][Full Text] [Related]
31. Th22 cell accumulation is associated with colorectal cancer development. Huang YH; Cao YF; Jiang ZY; Zhang S; Gao F World J Gastroenterol; 2015 Apr; 21(14):4216-24. PubMed ID: 25892871 [TBL] [Abstract][Full Text] [Related]
35. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Sabel MS; Su G; Griffith KA; Chang AE Breast Cancer Res Treat; 2010 Jul; 122(2):325-36. PubMed ID: 19802695 [TBL] [Abstract][Full Text] [Related]
36. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077 [TBL] [Abstract][Full Text] [Related]
37. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 Puca E; Probst P; Stringhini M; Murer P; Pellegrini G; Cazzamalli S; Hutmacher C; Gouyou B; Wulhfard S; Matasci M; Villa A; Neri D Int J Cancer; 2020 May; 146(9):2518-2530. PubMed ID: 31374124 [TBL] [Abstract][Full Text] [Related]
38. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3. Tang Q; Jiang J; Liu J Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948 [TBL] [Abstract][Full Text] [Related]
39. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Wang YQ; Ugai S; Shimozato O; Yu L; Kawamura K; Yamamoto H; Yamaguchi T; Saisho H; Tagawa M Int J Cancer; 2003 Jul; 105(6):820-4. PubMed ID: 12767068 [TBL] [Abstract][Full Text] [Related]
40. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions. Stoppacciaro A; Forni G; Colombo MP Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]